Solifenacin (Bispec (10 mg)) is a urinary antispasmodic agent, prescribed for overactive bladder with or without incontinence.It works by blocking the action of certain chemicals in the body to help ...
The US Food and Drug Administration (FDA) has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with solifenacin succinate (Vesicare, Astellas Pharma) for the treatment of overactive ...
With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Advisory Alert: It has come to our attention ...
Shares of pharma major Glenmark Pharma rose as much as 2.5 percent intraday Thursday as it has received tentative USFDA nod for Solifenacin Succinate tablets. "Glenmark Pharmaceuticals Inc., USA has ...
NEW DELHI: Glenmark Pharmaceuticals today said the US health regulator has granted tentative approval for tablets used for treatment of overactive bladder. The company has been granted tentative ...
Astellas Pharma announced results from the Phase 3b BESIDE trial of solifenacin (SOLI) with mirabegron (MIRA) as an add-on therapy in incontinent overactive bladder (OAB) patients. The BESIDE study is ...
The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Solifenacin (Soliten (10 mg)) is a urinary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results